On the agenda:
- Venous thromboembolism (VTE) in cancer in contemporary era
- Contemporary breast cancer treatment-associated thrombosis
- Machine learning for risk stratification of cancer-associated thrombosis (CAT)
- VTE and risk stratification in hematological malignancies
- P-Selectin as an emerging target for cancer therapy
- Cancer genetic alterations and risk of VTE
- The role of neutrophil extracellular traps in cancer-associated thrombosis
- Role and regulation of TFPI and FV in tumor cells
- Bi-directional cross talk between coagulation and cancers: Current assessment of pre-clinical evidence
- PET scan for occult cancer among patients with unprovoked VTE: What do we know?
- The relationship between platelets and cancer cells in the growing thrombus and in the development of cancer
- Debate: Catheter-associated thrombosis in cancer patients: To prophylax or not to prophylax?
- Venous and arterial thromboembolism in patients with cancer treated with targeted anti-cancer treatments
- Drug-drug interactions: Implications for anticoagulation use in patients with cancer
- Bleeding risk with direct oral anticoagulants in cancer patients
- Cancer and COVID-19: Where are the data?
- COVID-19-associated coagulopathy and thrombosis in cancer
- Roundtable: Multidisciplinary approach in cardiovascular oncology: Building a CAT Clinic - Real-World Systems Approaches to Prevention
- Cardiotoxic effects of antitumor agents: Pathogenetic mechanisms
Possible contact: firstname.lastname@example.org
Centro Congressi Giovanni XXIII
May 27-29, 2022